RG7834
RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells[1].
Product Specifications
CAS Number
[2072057-17-9]
Product Name Alternative
RO 7020322; (S) -RO0321
UNSPSC
12352005
Target
HBV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/RG7834.html
Purity
99.85
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(O)C1=CN2[C@@H](CC3=CC(OCCCOC)=C(C=C3C2=CC1=O)OC)C(C)C
Molecular Formula
C22H27NO6
Molecular Weight
401.45
References & Citations
[1]Han X, et al. Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. J Med Chem. 2018 Oct 4.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
129403-ML550 100 µL
MAPK3 (Mitogen-activated Protein Kinase 3, MAPK 3, MAP Kinase 3, ERT2, Extracellular Signal-regulated Kinase 1, ERK1, ERK-1, Insulin-stimulated MAP2 Kinase, MAP Kinase Isoform p44, Microtubule-associated Protein 2 Kinase, Mitogen-activated Protein Kinase 1, MAP Kinase 1, MAPK 1, P44ERK1, p44-ERK1, P44MAPK, p44-MAPK, PRKM3, MGC20180) (MaxLight 550)
Ask
View Details 
